Intravitreal administration of multipotent mesenchymal stromal cells triggers a cytoprotective microenvironment in the retina of diabetic mice
Author
dc.contributor.author
Ezquer, Marcelo
Author
dc.contributor.author
Urzúa Salinas, Cristhian
Author
dc.contributor.author
Montecino, Scarleth
Author
dc.contributor.author
Conget, Paulette
Author
dc.contributor.author
Ezquer, Fernando
Admission date
dc.date.accessioned
2016-06-29T22:05:40Z
Available date
dc.date.available
2016-06-29T22:05:40Z
Publication date
dc.date.issued
2016
Cita de ítem
dc.identifier.citation
Ezquer et al. Stem Cell Research & Therapy (2016) 7:42
en_US
Identifier
dc.identifier.issn
1757-6512
Identifier
dc.identifier.other
DOI 10.1186/s13287-016-0299-y
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/139290
General note
dc.description
Artículo de publicación ISI
en_US
Abstract
dc.description.abstract
Background: Diabetic retinopathy is a common complication of diabetes and the leading cause of irreversible vision
loss in the Western world. The reduction in color/contrast sensitivity due to the loss of neural cells in the ganglion cell
layer of the retina is an early event in the onset of diabetic retinopathy. Multipotent mesenchymal stromal cells (MSCs)
are an attractive tool for the treatment of neurodegenerative diseases, since they could differentiate into neuronal cells,
produce high levels of neurotrophic factors and reduce oxidative stress. Our aim was to determine whether the
intravitreal administration of adipose-derived MSCs was able to prevent the loss of retinal ganglion cells in
diabetic mice.
Methods: Diabetes was induced in C57BL6 mice by the administration of streptozotocin. When retinal pro-damage
mechanisms were present, animals received a single intravitreal dose of 2 × 105 adipose-derived MSCs or the vehicle.
Four and 12 weeks later we evaluated: (a) retinal ganglion cell number (immunofluorescence); (b) neurotrophic factor
levels (real-time quantitative polymerase chain reaction (RT-qPCR) and enzyme-linked immunosorbent assay (ELISA));
(c) retinal apoptotic rate (TUNEL); (d) retinal levels of reactive oxygen species and oxidative damage (ELISA); (e) electrical
response of the retina (electroretinography); (f) pro-angiogenic and anti-angiogenic factor levels (RT-qPCR and ELISA); and
(g) retinal blood vessels (angiography). Furthermore, 1, 4, 8 and 12 weeks post-MSC administration, the presence of donor
cells in the retina and their differentiation into neural and perivascular-like cells were assessed (immunofluorescence and
flow cytometry).
Results: MSC administration completely prevented retinal ganglion cell loss. Donor cells remained in the vitreous cavity
and did not differentiate into neural or perivascular-like cells. Nevertheless, they increased the intraocular levels of several
potent neurotrophic factors (nerve growth factor, basic fibroblast growth factor and glial cell line-derived neurotrophic
factor) and reduced the oxidative damage in the retina. Additionally, MSC administration has a neutral effect on
the electrical response of the retina and did not result in a pathological neovascularization.
Conclusions: Intravitreal administration of adipose-derived MSCs triggers an effective cytoprotective microenvironment
in the retina of diabetic mice. Thus, MSCs represent an interesting tool in order to prevent diabetic retinopathy.